Cargando…
Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disease in which immunoglobulin G (IgG) antibodies (Abs) bind to acetylcholine receptors (AChR) or to functionally related molecules in the postsynaptic membrane at the neuromuscular junction. IgG crystallizable fragment (Fc)-mediated effector functions, such...
Autores principales: | Keller, Christian W., Pawlitzki, Marc, Wiendl, Heinz, Lünemann, Jan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198115/ https://www.ncbi.nlm.nih.gov/pubmed/34071155 http://dx.doi.org/10.3390/ijms22115755 |
Ejemplares similares
-
Neonatal Fc Receptor–Targeted Therapies in Neurology
por: Nelke, Christopher, et al.
Publicado: (2022) -
Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis
por: Gable, Karissa L., et al.
Publicado: (2020) -
FcRN receptor antagonists in the management of myasthenia gravis
por: Bhandari, Vinaya, et al.
Publicado: (2023) -
Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
por: Vu, Tuan, et al.
Publicado: (2023) -
FcRn inhibitors: a novel option for the treatment of myasthenia gravis
por: Zhu, Li-Na, et al.
Publicado: (2023)